Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors
Jiani Wang, Lin Gui, Yuxin Mu, Jiayu Wang, Yihebali Chi, Zhenteng Liu, Qing Li, Binghe Xu · 2023
Read Phase I dose escalation study and pilot efficacy analysis of LXI-15029, a novel mTOR dual inhibitor, in Chinese subjects with advanced malignant solid tumors by Jiani Wang, Lin Gui, Yuxin Mu, Jiayu Wang, Yihebali Chi, Zhenteng Liu, Qing Li, Binghe Xu (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10702058.txt.
Description
Jiani Wang and seven co-authors report a 2023 early trial of a new cancer drug in China. The drug, LXI-15029, blocks mTOR, a switch that helps tumors grow. It was the first time the drug was given to people, so the main aim was safety.
Twenty-four patients with advanced solid tumors that no longer met standard care took the drug twice a day. Doses rose step by step from 10 to 150 mg across groups. The drug was well borne at all doses, with one case of raised liver enzyme at the top dose. The team also tracked how the body handled the drug and saw early signs of effect.
Catalog record
| CREATOR | Jiani Wang, Lin Gui, Yuxin Mu, Jiayu Wang, Yihebali Chi, Zhenteng Liu, Qing Li, Binghe Xu |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |